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PREAMBLE
Articles published in this issue of the Acta Clinica Croatica had been prepared for oral presentations at the 
Conference on Thyroid cancer, held on November 20th, 2020. in Zagreb, Croatia. The conference was organised 
by Croatian Thyroid Society and Croatia Society for Head and Neck Tumors under the auspices of the Croatian 
Academy of Science and Arts. Prior to acceptance and publication, all articles had undergone double review 
process, CrossRef similarity check and language editing.
In recent years, there has been a significant increase in the incidence of malignant thyroid tumors worldwide. 
The main reasons are the improvement and availability of diagnostic procedures such as ultrasound and fine 
needle aspiration cytology (FNAC), which have become the gold standard in diagnostics.
At the same time, there have been significant changes in the treatment of thyroid disease. The extent of 
 thyroid surgery, management of clinically negative neck and indications for the use of iodine-131 are procedures 
that today provoke a lot of debate in order to apply more sparing procedures with the best possible therapeutic 
effect.
A lot of attention was paid to the development of targeted therapies in the treatment of more aggressive 
forms of the disease with a poorer prognosis probably due to protein mutations, mainly tyrosine kinase enzyme 
that plays a significant role in tumor growth and proliferation. The discovery of new, targeted therapies and 
 improved understanding of thyroid carcinogenesis has led to great interest in the use of biologically targeted 
drugs and in the treatment of thyroid cancer, primarily in the treatment of medullary thyroid cancer as well as 
differentiated thyroid cancer refractory to radioactive iodine.
Genetic testing and a personalized approach that takes into account variability in the genetic characteristics, 
environment and lifestyle are increasingly present in the treatment of tumors in general and have their place in 
the treatment of thyroid cancer. Optimal treatment of thyroid tumors is possible only by a multidisciplinary 
 approach that includes a variety of specialties such as nuclear medicine specialists, head and neck surgeons, 
 endocrinologists, radiologists, oncologists, geneticists, speech therapists and others.
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